肿瘤细胞治疗研究
英文原题：Base Editing Might Be Key to CAR T-cell Therapy.
在接受这些 BE-CAR7 T 细胞的 11 例 T 细胞急性淋巴细胞白血病患者中，所有患者在 28 天后均获得完全形态学缓解，82% 接受了干细胞移植，64% 在治疗后 3 至 36 个月仍处于缓解状态。
研究者采用一种独特的碱基编辑策略，工程化制备嵌合抗原受体（CAR）T细胞，使其能够在宿主体内植入，并避免被残留抗体药物识别。在接受这些BE-CAR7 T细胞治疗的11例T细胞急性淋巴细胞白血病患者中，所有患者在28天后均达到形态学完全缓解；82%接受了干细胞移植；治疗后3至36个月，64%仍处于缓解状态。
Researchers used a unique base-editing strategy to engineer chimeric-antigen receptor (CAR) T cells that engraft in the host and remain invisible to remaining antibody drugs. Of the 11 patients with T-cell acute lymphoblastic leukemia who received these BE-CAR7 T cells, all had complete morphogenic remission after 28 days, 82% underwent stem-cell transplantation, and 64% remain in remission 3 to 36 months after treatment.
MEMBER ACCOUNT
登录成功会直接打开下一页。
